ENDRA Life Sciences Inc. (NDRA) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. ENDRA Life Sciences Inc. is a biotechnology company developing Thermo-Acoustic Enhanced Ultrasound (TAEUS) technology for non-invasive tissue characterization, specifically targeting liver fat assessment for metabolic disease management. The company is classified as a non-accelerated filer and a smaller reporting company. As of May 15, 2025, there were 738,370 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,036,330) | $(2,775,700) |
| Net Loss Per Share (Basic/Diluted) | $(1.86) | $(449.58) |
| Cash and Cash Equivalents (End of Period) | $2,064,874 | $1,134,701 |
| Net Cash Used in Operating Activities | $(1,293,129) | $(2,144,312) |
| Total Assets | $3,170,598 | $4,452,362 |
| Total Liabilities | $1,417,713 | $1,891,996 |
| Warrant Liability | $390,722 | $799,284 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 47% to $1.47 million from $2.78 million in Q1 2024.
- Research & Development: Decreased 49% to $528,685 as the company shifted focus from initial product development to clinical trials and commercialization.
- Sales & Marketing: Decreased 71% to $68,991 following a restructuring of sales operations in Q2 2024.
- General & Administrative: Decreased 42% to $871,606, driven by reduced wage expenses and professional fees.
- Warrant Liability Gain: The company recognized a non-cash gain of $408,562 due to a decrease in the fair value of warrant liabilities, significantly reducing the net loss compared to the prior year.
- Capital Structure: The company executed two reverse stock splits in late 2024 (1-for-50 and 1-for-35). All historical per-share data has been retroactively restated.
- Inventory: Inventory remains fully reserved at $0 value due to a 100% reserve against $2.5 million of recorded costs, with no pending orders for TAEUS systems.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. With an accumulated deficit of $104.5 million and cash burn of approximately $1.3 million per quarter, the company requires additional financing to fund operations for the next 12 months.
- Financing Strategy: The company is utilizing an At-The-Market (ATM) equity offering program. In Q1 2025, it raised $145,803. Subsequent to the quarter end, an additional $834,353 was raised via the ATM program.
- Strategic Pivot: Management is transitioning to a subscription-based business model for its TAEUS platform, targeting pharmaceutical companies, CROs, and primary care networks for metabolic disease monitoring.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of March 31, 2025, citing a material weakness due to insufficient accounting personnel to segregate duties.
- Risks: Key risks include the inability to secure additional capital, delays in FDA regulatory approval for the NAFLD TAEUS application, and the potential need to curtail operations or cease business if funding is not obtained.
Investor Verification Checklist
- Cash Runway: Verify current cash balance against the reported burn rate of ~$1.3M/quarter to assess immediate liquidity risk.
- ATM Program Capacity: Confirm remaining capacity under the February 2024 ATM agreement (up to $6.2 million gross proceeds) and recent issuance activity.
- Warrant Liability Volatility: Monitor the fair value of the $390k warrant liability, as fluctuations significantly impact reported net income/loss.
- Regulatory Milestones: Track progress on the de novo FDA application for the NAFLD TAEUS system, which is critical for future revenue generation.
- Internal Control Remediation: Review future filings for updates on hiring accounting personnel to address the material weakness in internal controls.